November 2014

CRANBURY, N.J., Nov. 18, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2014.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): €7.5M ($9.8M) …

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2015 Results; Teleconference and Webcast to be held on November 18, 2014 Read More »

CRANBURY, N.J., Nov. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2015 operating results on Tuesday, November 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 18, …

Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2015 Results Read More »

RED BANK, N.J., Nov. 4, 2014 /PRNewswire/ — Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress …

Survey Reveals Low Sexual Desire Disrupts Relationships Read More »